Bioenergetics governs all biological processes, with cellular metabolism acting as the central regulator of biological function and health. Metabolic pathway activities serve as critical biomarkers in drug discovery and development, and as robust predictors of drug efficacy and safety. Doppelganger's QSM™ platform quantifies metabolite turnover rates across the 22 principal metabolic pathways, including key aspects of cellular bioenergetics such as glycolysis and oxidative phosphorylation (OXPHOS), in all major disease areas. The QSM™ platform has been validated for use with single cells (single-cell seahorse analysis”) and various tissue types, including formalin-fixed, paraffin-embedded (FFPE) tissues.

Doppelganger Biosystem GmbH (Germany) supports scientists in preclinical, clinical, and translational research by providing crucial insights into the function and activity of central cellular metabolic pathways. Neuroproof GmbH is our preferred partner in microelectrode array (MEA)-based phenotypic screening.

​

Want to learn more about QSM™?